Psychedelic therapy Psychedelic therapy Psychedelic therapy refers to therapeutic practices involving psychedelic drugs, oftentimes utilizing serotonergic psychedelics such as LSD, psilocybin, DMT, MDMA, mescaline, and 2C-B. Psychedelic therapy, in contrast to conventional psychiatric medication taken by the patient regularly or as-needed, patients generally remain in an extended psychotherapy session during the acute psychedelic activity with additional sessions both before and after in order to help integrate experiences with the drug. Psychedelic therapy, in the broadest possible sense of the term, may have originated from prehistoric knowledge of hallucinogenic plants. They grow naturally in certain cacti, seeds, bark and roots of various plants.
Boldenone Boldenone acts similar to metandienone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and associated progestogenic side effects. Boldenone, also known as Δ-testosterone, 1-dehydrotestosterone, or androsta-1,4-dien-17β-ol-3-one, is a naturally occurring androstane steroid and a derivative of testosterone. It is specifically testosterone with a double bond between the C1 and C2 positions. A related compound is quinbolone, the 17-cyclopentenyl enol ether of boldenone. Boldenone occurs naturally in the scent gland of "Ilybius fenestratus", a species of aquatic beetle. Ciba reportedly patented boldenone in 1949. It subsequently developed several experimental esters of the drug in